

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A purified antibody for ~~modulating a biological activity~~ inhibiting growth of a malignant cell that expresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an amino terminal extracellular domain of the frizzled 5 receptor expressed on the malignant cell, and wherein the amino terminal extracellular domain is SEQ ID NO:68.
2. (Previously presented) The purified antibody of claim 1, wherein the extracellular domain comprises an amino terminal peptide fragment of the frizzled 5 receptor.
3. (Original) The purified antibody of claim 1 further comprising an antibody fragment having an antigen binding region that specifically binds to the epitope.
4. (Currently amended) The purified antibody of claim 1, wherein the antibody is capable of ~~sensitizing~~ eliciting a cytotoxic response of the malignant cells expressing the frizzled 5 receptor ~~to a cytotoxic factor.~~
5. (Previously presented) The purified antibody of claim 1, wherein the antibody inhibits binding of a Wnt ligand to the frizzled 5 receptor.
6. (Original) The purified antibody of claim 1 further comprising a detectable label.
7. (Original) The purified antibody of claim 1, wherein the antibody is a human antibody.
8. (Original) The purified antibody of claim 1, wherein the antibody is a monoclonal antibody.

9-15. (Cancelled)

16. (Currently amended) A pharmaceutical composition comprising a purified antibody for ~~modulating a biological activity~~ inhibiting growth of a malignant cell that expresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an amino terminal extracellular domain of the frizzled 5 receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier, and wherein the amino terminal extracellular domain is SEQ ID NO:68.

17-27. (Cancelled)

28. (New) A purified antibody for immunotherapy of a malignant cell that overexpresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope of the amino terminal extracellular domain of the frizzled 5 receptor expressed on the malignant cell, and wherein the amino terminal extracellular domain is SEQ ID NO:68.

29. (New) A pharmaceutical composition comprising the purified antibody of claim 28.